STABILITY INDICATING ISOCRATIC HPLC APPROACH TO QUANTIFY MONTELUKAST AND BILASTINE MIX IN BULK AND TABLET FORMULATION
Authors:
- Balaji Gupta V.L.N. TiruveedhiBTBalaji Gupta V.L.N. Tiruveedhi
- Venkateswara Rao BattulaVBVenkateswara Rao Battula
- Kishore Babu BonigeKBKishore Babu Bonige
- Ramanjaneyulu V. V. MatlapudiRMRamanjaneyulu V. V. Matlapudi
- 28 May 2023
- journal article
- research article
- Published by Indian Drug Manufacturers' Association (IDMA) in INDIAN DRUGS
- Vol. 60 (05) , 57-65
Abstract
This paper describes an novel, rapid, simple, meticulous and unerring “stability indicating HPLC method” for the assessment of montelukast (MTT) and bilastine (BLE) mix in existence of their degradation products in tablet formulation. Zorbax column XDB-C18 was utilized to separate and analyse MTT and BLE mix. The isocratic mode elution of BLE and MTT mix was made with 0.1M disodium hydrogen phosphate buffer of pH 5.8 (55 % volume ratio) and methanol (45% volume ratio) at 1.0 mL min-1 flow stream. Strong linearity was recorded within the 2.5 - 20 µg mL-1 and 5 - 40 µg mL-1 concentration ranges, with coefficient determination values of 0.9994 and 0.9997, respectively, for MTT and BLE. The recovery percentiles of MTT and BLE were 99.593 % and 99.349 %, respectively. The precision displayed values less than 0.520 % for MTT and less than 0.745 % for BLE. The robustness too was shown in the chromatographic settings by minor variations. The specificity besides stability representing feature was evidenced since the degradation products arisen in stress situations did not interlope in the determination of MTT and BLE mix. Thus, this procedure can be applied for quality regulation analysis of BLE and MTT mix in formulations of tablets.Keywords
This publication has 10 references indexed in Scilit:
- Montelukast use over the past 20 years: monitoring of its effects and safety issuesClinical and Experimental Pediatrics, 2020
- Role of bilastine in allergic rhinitis: a reviewInternational Journal of Otorhinolaryngology and Head and Neck Surgery, 2020
- Bilastine: a lifetime companion for the treatment of allergiesCurrent Medical Research and Opinion, 2019
- Concomitant bilastine and montelukast as additive therapy for seasonal allergic rhinoconjunctivits and mild‐to‐moderate asthma. The SKY studyAllergy, 2019
- Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's diseaseJournal of Ethnopharmacology, 2018
- Drug combination therapy increases successful drug repositioningDrug Discovery Today, 2016
- Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastineTherapeutics and Clinical Risk Management, 2016
- Bilastine: new insight into antihistamine treatmentClinical and Molecular Allergy, 2015
- Development of forced degradation and stability indicating studies of drugs—A reviewJournal of Pharmaceutical Analysis, 2014
- Montelukast in asthma: a review of its efficacy and place in therapyTherapeutic Advances in Chronic Disease, 2010